Tenon Medical Inc

Tenon Medical Inc(TNON)の株式分析

$1.770

+0.117 (+6.63%)終値時点

Loading chart…
高値
1.800
始値
1.660
出来高加重平均価格
1.74
出来高
94.11K
時価総額
2.31M
安値
1.650
売買代金
163.75K
EV/EBITDA(TTM)
-0.37

Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant.

www.tenonmed.com

AI分析 of Tenon Medical Inc (TNON)

売り

Tenon Medical Inc is not a good buy right now due to its extremely low RSI of 13.34, indicating it is oversold, and a staggering year-to-date change of -95.13%. The stock is trading at $1.66, significantly below its 52-week high of $45.50, which reflects a severe decline in value. The company has also reported consistent net losses, with the latest EPS at -12.35, and a forward P/E ratio of 0, suggesting no earnings growth is expected in the near term. The main risk is the negative sentiment surrounding its financing activities, which caused a 4.79% drop in pre-market trading after the announcement of a securities purchase agreement.

バリュエーション指標

Tenon Medical Inc(TNON)の現在の予想PERは0.00で、5年平均は-3.02です。

予想PER

適正
5年平均 P/E
-3.02
現在のP/E
0.00
割高
12.73
割安
-18.77

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
-0.05
現在のEV/EBITDA
-0.37
割高
0.06
割安
-0.17

予想PSR

適正
5年平均 P/S
5.63
現在のP/S
0.50
割高
36.11
割安
-24.85

Alphio AI による TNON の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%TNON

$1.25

シナリオ価格

基

基本

基本 · 50%TNON

$1.02

シナリオ価格

弱

弱気

弱気 · 25%TNON

$0.83

シナリオ価格

イベントタイムライン

2026-10-28 (ET)

09:25:00

Tenon Medical Completes Initial Alpha Cases for Quickstep

2026-10-15 (ET)

09:00:00

Tenon Medical Secures 8 New Patents

2026-10-05 (ET)

06:30:00

Selling Stockholders Plan to Sell 858,269 Shares of Common Stock

2026-09-30 (ET)

09:00:00

Tenon Medical Launches New Titanium 3D-Printed Lateral Screw

2026-09-11 (ET)

11:00:00

Tenon Medical Inc Trading Halted

ニュース

TNON のよくある質問 — Alphio AI が回答

Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tenon Medical Inc is not a good buy right now due to its extremely low RSI of 13.34, indicating it is oversold, and a staggering year-to-date change of -95.13%. The stock is trading at $1.66, significantly below its 52-week high of $45.50, which reflects a severe decline in value. The company has also reported consistent net losses, with the latest EPS at -12.35, and a forward P/E ratio of 0, suggesting no earnings growth is expected in the near term. The main risk is the negative sentiment surrounding its financing activities, which caused a 4.79% drop in pre-market trading after the announcement of a securities purchase agreement.

コミュニティ

もっと見る ↗
登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める